Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.

She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.

Dr Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD theses and post-doc fellows. He is also head of Clinical Chemistry Department in the Cliniques universitaires St Luc, Brussels, in charge of the automated CoreLab platform as well as of the analytical biochemistry platform regrouping specific activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry and endocrinology (GC, HPLC, UPLC, LC-MSMS, GC-MS).

He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author of more than 180 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 200 conferences on invitation. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas. Pierre Wallemacq is the past-president of the Royal Belgian Society of Clinical Chemistry (SRBCC-KBVKC), and is the current president of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. He received the IATDMCT C.E. Pippenger award in 2011 for outstanding contribution to Therapeutic drug Monitoring, and was nominated member of the Royal Belgian Academy of Medicine (ARMB) in 2012.

Employment

• 2010- Professor in Clinical Pharmacology
  Internist-clinical pharmacologist, Dept Hospital Pharmacy, Erasmus Medical Center - Rotterdam - NL
  Internist-nephrologist, Dept Internal Medicine, Erasmus Medical Center - Rotterdam - Netherlands
• 2002-2010 Internist-clinical pharmacologist, Dept Hospital Pharmacy
  Internist-nephrologist, Dept Internal Medicine
  Both at Erasmus Medical Center - Rotterdam - The Netherlands
• 2000-2002 Head of the Renal Transplantation Unit - Dept Internal Medicine - Erasmus Medical Center
• 1998-1999 Post-doctoral fellow Dept Cardiothoracic Surgery -
  Laboratory for Transplantation Immunology, Stanford University - Palo Alto - USA
• 1996-1998 Internist-nephrologist, Erasmus Medical Center - Rotterdam - The Netherlands
• 1993-1996 Internist, Erasmus Medical Center - Rotterdam - The Netherlands
• 1988-1993 Resident Internal Medicine, Erasmus Medical Center - Rotterdam - The Netherlands
• 1987-1988 MD in (mandatory) Military Service

Education & Certification

• Clinical Pharmacology (certification: December 1, 2003)
  Trained at University Medical Center Nijmegen – Netherlands in 2002-2003
• Post-doctoral fellowship (Transplantation Immunology)
  Stanford University 1998-1999 (Professor Randall E Morris)
• Thesis (Erasmus University Rotterdam) date : May 15, 1996 PhD. Title of thesis "The role of anti Interleukin-2 receptor monoclonal antibody (BT563) in the prevention of acute rejection after organ transplantation"
• Nephrology (certification April 16, 1996)
  Trained at University Hospital Rotterdam 1995-1996
• Internal Medicine (certification May 1, 1993)
  Trained at University Hospital Rotterdam 1988-1993
• Medicine (certification as MD at Feb 20, 1987)
  Trained at Erasmus University Rotterdam 1980-1987 MD

Professional Activities

• Since 2003 member of IATDMCT.
• From 2005-2009 Councilor of IATDMCT
• From 2009-2013 Director of Education within Council of IATDMCT
• From 2009-2013 Chair of Immunosuppressive drugs committee of IATDMCT
• From 2009 - 2015 Secretary of Dutch Transplantation Society
• Since 2011 Chairman of Dutch Society for Clinical Pharmacology and Biopharmacy

Web-of-Science: 346 publications, H-index 39, with 6079 citations (as of March 2015)
Speaker at numerous conferences, both national and international.

Awards

• 1994 Nephrology Award (Dutch Society for Nephrology)
• 1996 Jon J. van Rood Award (Dutch Transplantation Society)
• 1997 Young Investigator Award (European Society Heart Lung Transplantation)
• 1998 International Young Investigator Award (American Society Transplant Physicians)
• 2000 International Young Investigator Award (American Society of Transplantation)
• 2005 Outstanding Speaker Award (American Association for Clinical Chemistry)
• 2009 Visiting Professor Nephrology West China Medical School Chengdu (China)
• 2010 Visiting Professor (Kathleen Valles Chair) St George’s Medical School London (UK)
• 2011 Teacher of the year award (medical students – Erasmus University Rotterdam)

Vision Statement

Therapeutic drug monitoring and analysis+consulting for clinical toxicology are forms of personalized medicine “avant la lettre”. IATDMCT has promoted the individualization of treatment before the term personalized medicine had even been invented. Our strength is the analytical expertise and translation of laboratory results into practical treatment recommendations . My mission will be to promote the added value of our contribution, to increase the visibility of IATDMCT and to increase involvement of clinicians into our Association. 

Professor Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan. He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. He has been studying clinical pharmacokinetics and pharmacodynamics mainly in oncology and infectious diseases. His modeling and simulation studies on population pharmacokinetics and pharmacodynamics were applied to new drug development as well as rational use for routine patient care. He also investigates multi-omics biomarkers such as genomics, proteomics and metabolomics as factors causing individual variation in drug response. He is distinguished as one of the "ISI Highly Cited Researchers."

Employment

• 1998-present, Professor, Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Japan
• 1998-2007, Director of Hospital Pharmacy, Keio University Hospital, Japan
• 1993-1998, Associate Professor and Vice Director, Department of Pharmacy, Kobe University Hospital, Japan
• 1991-1992, Honorary Research Fellow, School of Pharmacy, University of Manchester, U.K.
• 1990-1993, Lecturer, Department of Pharmacy, Kyoto University Hospital
• 1985-1990, Instructor, Department of Pharmacy, Kyoto University Hospital

Education & Certification

• Board Certified Senior Clinical Pharmacist (BCSCP), Japanese Society of Clinical Pharmacology and Therapeutics
• Board Certified Clinical Pharmacist (BCCP), Japanese Society of Clinical Pharmacology and Therapeutics
• JSPHCS-certified Senior Oncology Pharmacist (JSOP), Japanese Society of Pharmaceutical Health Care and Sciences
• Board Certified Oncology Pharmacy Specialist (BCOPS), Japanese Society of Hospital Pharmacists
• Pharmacist License of Japan • 1983, Ph.D. from Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
• 1980, MSc from Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
• 1978, BSc from Faculty of Pharmaceutical Sciences, Kyoto University, Japan

Professional Activities

• 2013-2015, IATDMCT Secretary
• 2015-, Chair of Scientific Committee “TDM in Oncology”
• 2017, Chairman, 15th IATDMCT Congress 2017 in Kyoto
• Editorial Board, Therapeutic Drug Monitoring • 2005-2011, President, Japanese Society of Therapeutic Drug Monitoring (JSTDM)
• Plenary Lecturer at 12th Congress of IATDMCT 2011 in Stuttgart
• Invited speaker at IATDMCT Regional Meeting in Sibiu, 2014
• Invited speaker at IATDMCT Regional Meeting in China, 2010
• Symposium speaker and organizer at IATDMCT (1995 in Vienna, 1999 in Cairns, 2009 in Montreal)
• Number of peer reviewed original articles: 159
• Book chapters and Review articles: 190
• Invited lectures at international conferences: 39
• Invited lectures at Japanese national conferences: 108
• Dr. Tanigawara is distinguished as “Highly Cited Researcher” by Thomson Reuters ISI database. His research interests include clinical pharmacokinetics, pharmacodynamics and pharmacogenomics and their applications to TDM. He also investigates multi-omics biomarkers by means of MS-based proteomics and metabolomics.

Other academic and professional appointments:

• 2006-present, President, Population Approach Group in Japan
• 2007-2009, Delegate for the Board of Pharmaceutical Sciences, International Pharmaceutical Federation (FIP)
• 2005-2008 and 2010-2014, Executive Board member, Japanese Society of Clinical Pharmacology and Therapeutics
• 2008-present, Executive Board member, Japanese Society of Pharmaceutical Health Care and Science
• 2007-2009, Executive Board member, The Pharmaceutical Society of Japan • 2005-present, Council member, Japanese Society of Clinical Oncology
• 2007-present, Council member, Japanese Society of Medical Oncology
• 2009-present, Council member, Japanese Cancer Association
• 2003-present, Council member, Japanese Society of Chemotherapy
• 2003-present, Council member, Japanese Society for Pharmacoepidemiology
• 2002-present, Associated Editor, Cancer Science
• 2005-present, Editorial Board, Japanese Journal of Clinical Oncology
• 2006-present, Editorial Board, International Journal of Clinical Oncology
• 2010-present, Editorial Board, The Japanese Journal of Antibiotics
• 1999-2001, Editorial Board, European Journal of Pharmaceutical Sciences

Vision Statement

As the current Secretary, I have been working hard to expand the IATDMCT network worldwide. During last 2 years, the Association has significantly grown due to the increased number of members particularly in Asian region. I am pleased to make efforts to contribute to the IATDMCT as Secretary.

Gwendolyn A. McMillin received a BA from Grinnell College, in Grinnell, IA, and a PhD in pharmacology and toxicology from the University of Utah, in Salt Lake City, UT. She completed post-doctoral training in Clinical Chemistry through the University of Utah, and is certified by the American Board of Clinical Chemistry (ABCC) in the areas of Clinical Chemistry and Toxicological Chemistry. She is currently an Associate Professor (clinical) of Pathology at the University of Utah, and is a Medical Director at ARUP Laboratories, responsible for the areas of Clinical Toxicology and Pharmacogenomics.

Dr McMillin is actively involved in professional associations. For example, she served as Chair of the TDM/Toxicology Division of the American Association for Clinical Chemistry (AACC), Chair of the Toxicological Chemistry exam and Continuing Education Committee for the American Board of Clinical Chemistry (ABCC), a Member of the Toxicology Resource Committee for the College of American Pathologists (CAP), and is co-Chair of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology's (IATDMCT) 2013 Congress. She was also involved in forming the Personalized Medicine Division of the AACC. Dr McMillin serves as an Editorial Board member for professional journals such as Therapeutic Drug Monitoring and the Journal of Analytical Toxicology, and has published nearly 100 original research manuscripts, review articles, and book chapters. Her research is focused on evaluating and assuring clinical utility of drug testing and pharmacogenomics, funded by several commercial contracts and federal grants.

Employment

• 2003-Present:  Medical Director, Toxicology and Pharmacogenomics, ARUP Laboratories, Inc., Salt Lake City, UT, USA
• 2014-Present:  Professor (Clinical), University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA
• 2010-2014:  Associate Professor (Clinical), University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA
• 2004-2010:  Assistant Professor (Clinical), University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA
• 1996-2001:  Medical Director, Toxicology and Pharmacogenomics, ARUP Laboratories, Inc., Salt Lake City, UT, USA
• 1994-1996: Senior Scientist, University of Utah, Department of Pharmacology and Toxicology, Anticonvulsant Drug Development Program, Salt Lake City, UT, USA

Education & Certification

• 2005: Diplomate certification through American Board of Clinical Chemistry in Toxicological Chemistry
• 2004: Diplomate certification through American Board of Clinical Chemistry in Clinical Chemistry
• 1994: Ph.D. awarded in Pharmacology through the University of Utah, College of Pharmacy, Salt Lake City, UT, USA
• 1989: B.A. awarded in Psychology through Grinnell College, Grinnell, IA, USA

Professional Activities

Activities in IATDMCT:

• Current Treasurer; Co-chair of the 2013 annual meeting (SLC, UT);
• Contributing member of the Clinical Toxicology/Drugs of Abuse Committee;
• Invited speaker (DUPHAT 2014, IATDMCT 2015)

Activities in AACC (American Association for Clinical Chemistry):

• Current vice-chair of the 2016 annual meeting (Philadelphia, PA);
• Current officer in the Personalized Medicine Division;
• Former chair of the TDM/Toxicology Division (2009-2014);
• Symposium coordinator for annual meeting (2010);
• Chair nominating committee (2009-2010);
• Invited speaker at several annual and regional meetings

Activities in CAP (College of American Pathologists):

• Current member of the Toxicology Resource Committee and Pharmacology Working Group;
• Invited speaker at several annual meetings

Activities in ABCC (American Board of Clinical Chemistry):

• Board member, chair of Toxicology exam committee (2007-2012)

Editorial Board Member: Therapeutic Drug Monitoring; Journal of Analytical Toxicology

Active publication record:
I have authored/published in excess of 70 original manuscripts; 10 review articles; 25 book chapters; and 150 abstracts

My experience as IATDMCT Treasurer since 2013 has prepared me to serve on the Council.  I am organized and successful in completing projects in a timely manner, and I am both excited and privileged to have opportunity to continue serving the organization by managing the finances for another term. 

Mercè Brunet is Professor of Pharmacology and Toxicology at the University of Barcelona; Medical School of Barcelona. She is currently the Head of Pharmacology and Toxicology in the Biologic Diagnostic Center of the Hospital Clínic of Barcelona. She got her Ph.D. in Pharmaceutical Sciences from Barcelona University in 1980.

Mercè Brunet's main research interests are focus on treatment personalization, mainly concerning the measurement of biomarkers that may reflect immunosuppressive drugs’ exposure and effect, using pharmacokinetic, pharmacogenetic and pharmacodynamic approaches. Recently most of her work is dedicated to new pharmacokinetic/ pharmacodynamics monitoring strategies for antitumor drugs. She has published over 105 original articles in peer-reviewed international journals and 9 book chapters.

Employment

• Head of Pharmacology and Toxicology. Biologic Diagnostic Center. Hospital Clínic, University of Barcelona, Spain (2004-present).
• Professor of Pharmacology and Toxicology, Medical School, University of Barcelona (1996- present).
• Staff Member: Pharmacology Laboratory, 1987-2003, Hospital Clínic. University of Barcelona.
• Research fellow: Hospital Clínic, 1982-1986. University of Barcelona.
• Associate Professor of Medicine, 1994- 1996. University of Barcelona.

Education & Certification

• PhD Pharmacology, University of Barcelona (1993), Doctoral Thesis, Project: “Contribución al estudio de la toxicidad de los fármacos antiepilépticos. Efectos adversos sobre el. metabolismo de los esteroides”.
• B.S.C. University of Barcelona. School of Pharmacy (1980).
• Specialist in Biochemical Analysis. University of Barcelona (1990).
• Pharmacist Assistant, School of Pharmacy, University of Barcelona (1983).
• Good Laboratory Practices GLPs: Certified of Auditor (2000).

Professional Activities

IATDMCT Awards

• Director of Education of the IATDMCT Council (2013-2015).
• Councilor of the IATDMCT Council (2009-2011).
• Leader of the Biomarkers Working Group (BWG) of the Scientific Committee of Immunosuppressive Drugs at the IATDMCT. (2010-2015).
• Member of Scientific Committee of Immunosuppressive Drugs (2007-2015).

Activities in IATDMCT

• Coordinator of the Special issue of the First Consensus Document for promising biomarkers of immunosuppression in clinical transplantation: methods standardization and validation. Co- Educational Activity Project of the Biomarker Working Group. Project Coordination: Mercè Brunet, Michael Oellerich and Pierre wallemacq (2014-2015).
• Director of the IV Symposium on Biomarkers of Immunosuppression and Clinical Outcome in Transplantation: New Approaches on TDM of Immunosuppressive Drugs. Educational activity of the BWG of the Scientific Committee of IDs. IATDMCT. Scientific Coordination: M. Brunet and P. Wallemacq on behalf of the Biomarkers Working Group (BWG). Barcelona, December 11-12 2014.
• The Directors and Education designed a survey, to know the most important topics in education for our members, provided in the resources area of the IATDMCT website which has been active during February 2014 and was completed by 120 members.
• 14th IATDMCT Congress, the Netherlands, Rotterdam 2015. A proposal of the ISDs committee with topics to be included in specific Symposiums, such us biomarkers in transplantation, in the scientific program.Coordinators: Teun van Gelder, Maria Shipkova, Dennis Hesselink, Mercé Brunet.
• Member of the Scientific Committee of Experts of the 19 Congress of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Stuttgart November 2013.
• European Symposium on Clinical Immunosuppression Monitoring of Biomarkers in Transplantation (under the auspices of IATDMCT). Symposium Coordinator: M: Brunet. Speakers: Expert members of the IATDMCT (IDs Scientific Committee). Barcelona 2011. Published in Compass.
• Lecturre at IATDMCT Congress SLC 2013. Symposium S2502: Pharmacodynamic Monitoring Biomarkers of Immunosuppression in Transplantation. Mercè Brunet, Moderator: Leslie M.

Other Awards

• Secretary of the Council of the Spanish Society of Pharmacogenetics and Pharmacogenomics. (2012-present).
• Secretary of the Catalan Scientific Society of Transplantation. Academy of Medical Sciences of Catalonia and the Balearic Islands. (2009-present).
• Member of the Scientific Committee of Immunology of the Spanish Society of Transplantation (SET) (2014-2018).
• Member of the International Transplant Society (2002 - present).
• Member of CIBERehd-Networked Biomedical Research Center: Hepatic and Digestive Diseases.
• Member of the Reial Academia de Medicina de Catalunya I Balears.
• Member of the Editorial Boards of International Journals such us Therapeutic Drug Monitoring (TDM), Trends in Transplantation (TT).

Other Professional / Educational Activities (2010-2015)

• Master Coordinator: Master in Translational Medicine (Module1). University of Barcelona.
  www.ub.edu/medicina/masters/traslacional/.
• Course Director: The role of Mass Spectrometry in the Clinical Diagnostic Laboratories. Technical advances and new applications. Farmacologia i Toxicologia. Centre de Diagnòstic Biomèdic. Aula Clínic. Hospital Clínic. University of Barcelona. October 2011, October 2013.
• Scientific Organizing Committee: 12 Congres de la Societat Catalana de Trasplantament. Barcelona March 2013.
• Scientific Organizing Committee: 13 Congres de la Societat Catalana de Trasplantament. Barcelona March 2015.
• Scientific Organizing Committee of 4th and 5th Congreso de la Sociedad Española de Farmacogenética y Farmacogenómica (SEFF). Bilbao June 2013, Madrid April 2015.
• Scientific Organizing Committee: Curs Pre-congres de la Societat Catalana de Trasplantament (Formació de residents): 2 y 3 Curso práctico de trasplante de órganos sólidos. Barcelona, March 2013; March 2015.
• Lectures at Congreso Sociedad Española de Química Clínica (SEQC) Octubre 2014.
• Invited expert at a meeting “Graft-derived circulating cell-free DNA as a marker of graft integrity using Droplet Digital™ PCR” organized by M. Oellerich and BioRad (2014).

Publications

• Published over 150 original articles in peer-reviewed international journals and 12 book chapters.

Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.

From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland. 
Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of 100 peer-reviewed publications, 8 book chapters and 50 published oral or poster presentations.

Dr Rentsch is currently the head of the Swiss Society of Clinical Chemistry and she is a member of the IATDMCT, the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh), and several other local professional organizations. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.

Employment

• Since 2014 Head of Laboratory Medicine, University Hospital Basel, Switzerland
• Since 2011 Head of the Clinical Chemistry division, University Hospital Basel, Switzerland
• 2004-2011 Deputy Head of the Institute for Clinical Chemistry, University Hospital Zurich, Switzerland
• 1994-2011 Head of the laboratory for drug analysis and clinical toxicology, Institute for Clinical Chemistry, University Hospital Zurich, Switzerland
• 1991-1994 Scientist at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland
• 1990-1991 Head of the Laboratory for Special Analyses at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland
• 1989-1990 Scientist at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland

Education & Certification

• 2012 Adjunct professor („Titularprofessorin“), Medical faculty, University Basel, Switzerland
• 2010 Adjunct professor („Titularprofessorin“), Medical faculty, University Zürich, Switzerland
• 2007 Certification as „Clinical Toxicologist GTFCh“
• 2007 Habilitation for Clinical Chemistry at the Medical Faculty of the University Zürich, Switzerland
• 2003 Habilitation for Clinical Chemistry at the Department of Chemistry and Applied Biosciences, ETHZ, Zurich, Switzerland
• 1996 PhD dissertation at the Institute of Pharmaceutical Sciences, ETHZ, Zurich, Switzerland
• 1991 Certification as “Specialist for Laboratory Medicine” awarded by the FAMH (Swiss Association of the Heads of Medical Laboratories)
• 1988 Master of Science in Pharmacy, Swiss Federal Institute of Technology Zurich, (ETHZ), Switzerland; awarded pharmacist’s license

Professional Activities

Memberships and Activities in Scientific Societies

• International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
• The International Association of Forensic Toxicologists (TIAFT)
• American Association for Clinical Chemistry (AACC) - Society of Toxicological and Forensic Chemistry (GTFCh)
• Swiss Society of Clinical Chemistry (SSCC)
• Swiss Chemical Society (SCS)
• Swiss Group of Mass Spectrometry (SGMS)
• Swiss Association of the Heads of Medical Laboratories (FAMH)
• Swiss Federation of Pharmacists (pharmaSuisse)

Executive and committee positions held

• Vice president of the Society of Toxicological and Forensic Chemistry (GTFCh) (since 2015)
• Member of the GTFCh committee “Clinical Toxicology” (since 2001)
• Chair of the SSCC committee “Drug Monitoring” (since 2003)
• President of the Swiss Society of Clinical Chemistry (SSCC) (2009-2014)
• Vice president of the SSCC and chair of the scientific committee (2006-2008)
• Member of the board of the Division “Analytical Chemistry” of the Swiss Chemical Society (2006-2008)

Activities for IATDMCT

• Councillor of the IATDMCT 2007 – 2015
• Member of the Clinical Toxicology/Drugs of Abuse Committee (since 2006)
• Member of the Local Organizing Committee of the Stuttgart Meeting (responsible for roundtables). 2011
• Member of the Scientific Board of the Basle Meeting (responsible for CT breakfast roundtables), 2003

Number of Publications

• > 120 peer reviewed original papers and invited reviews
• > 60 published oral or poster presentations
• 8 book chapters Speaking engagements:
• > 100 invited lectures (universities, national and international meetings)

Professional Appointments

• Referee of scientific journals (e.g Clin Chem, J Chromatogr A and B, J Mass Spectrom, Anal Bioanal Chem, Anal Chem)
• Lecturer University Basel, Pharmaceutical Sciences: “Clinical Chemistry” including Therapeutic Drug Monitoring and Clinical Toxicology (3rd year Bachelor, 1st year Master)
• Lecturer University Basel Medical School: “Chemistry in Blood” (2nd year Bachelor)
• Lecturer Swiss Federal Institute of Technology (ETHZ), Medical and Industrial Pharmaceutical Scienses: “Bioanalytics” in the module “Clinical research and development” (1st year Master)
• Lecturer Swiss Federal Institute of Technology (ETHZ), Pharmaceutical Sciences: “Clinical Chemistry” including Therapeutic Drug Monitoring and Clinical Toxicology (3rd year Bachelor, 1st year Master) (until 2012)
• Lecturer University Zurich Medical School: “Therapeutic Drug Monitoring” (1st year Master) (ongoing), Clinical Toxicology (2nd year Bachelor), Clinical Chemistry (2nd year Bachelor, 1st year Master) (until 2011)

Employment

• 2003- Senior scientist and head TDM/Tox section, Institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany
• 1999- 2002 Resident Dept. of Clinical Chemistry, University Göttingen, Germany
• 1995-1999 Postdoctoral fellow, Dept. of Clinical Chemistry, University Göttingen, Germany
• 1992-1995 Resident Dept. of Clinical Chemistry, University Sofia, Bulgaria
• 1991-1992 Resident Dept. Internal Medicine, University Sofia, Bulgaria

Education & Certification

Academic Degrees

• Dr. med. University Göttingen, Germany, 2002
• D-r (BG)., University Sofia, Bulgaria, 1990,

Professional Registrations                        

• Fellow European Board of Laboratory Medicine/Medical Biopathology (F.E.B.L.M./M.B.), 2013
• Clinical Pathology Consultant, 1996

Professional Activities  

Professional Society Memberships

• Vereinte Deutsche Gesellschaft für Laboratoriumsmedizin und Klinische Chemie(DGKL)
• International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
• Transplantation Society

Publications

93 articles contributed to scientific journals on the following topics: therapeutic drug monitoring, drug metabolism, drug toxicity, development and evaluation of analytical methods, organ function tests, biomarkers of drug effects.

Stipends and Awards

• 2015 Grant from the Federal Ministry of Education and Research “Validation of GcfDNA based diagnostic test to detect organ damage after kidney transplantation”
• 2011 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Analytical validation of biomarker assays in transplantation medicine
• 2005 Young Investigator Award of the International Society for Therpaeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
• 2004 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Acyl glucoronides of mycophenolic acid
• 2002 Grant of the University Göttingen, Germany, Acyl glucuronide of mycophenolic acid
• 1998 Stipend Volkswagen Foundation, Germany, Metabolism of immunosuppressants
• 1996 Stipend Otvoreno Obschtestvo, Bulgaria, Pharmacokinetics of Taxol
• 1995 Tempus Phare stipend of the EU, Therapeutic Drug Monitoring

Varia

• Past Chair of the IATDMCT Immunosuppressive Drugs Scientific Committee
• Vice-Chair IATDMCT Communication Committee
• Coordinator “TDM of Everolimus” Consensus Project
• Past Editor in Chief of the IATDMCT Newsletter “Compass”
• Member of the Editorial Boards of Therapeutic Drug Monitoring (TDM)
• Reviewer of publication for: Journal of Chromatography, Clinical Chemistry, Clinical Biochemistry, Clinica Chimica Acta, Transplant International, etc.

Current Appointments

• Senior Specialist in Clinical Microbiology and Infectious Diseases St. Vincent's Hospital, Sydney (1985 - to date)
• Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group, St. Vincent’s Hospital, Sydney (2012 – to date)
• Visiting Medical Officer St. Vincent's Private Hospital, Sydney (1985 – to date)
• Visiting Medical Officer Sacred Heart Hospice, Sydney (1985 – to date)
• Conjoint Associate Professor, School of Medicine, University of New South Wales (2000 – to date)
• Adjunct Professor, Faculty of Science University of Technology, Sydney (2002 -to date)
• Associate Editor, Transplantation (2014 – to date)

Certifications

• Fellow of the Royal College of Pathologists of Australasia (FRCPA) 1986
• Fellow of the Royal Australasian College of Physicians (FRACP) 1985
• Bachelor of Medicine and Bachelor of Surgery, Honours Class I 1977
• Bachelor of Science (Medicine) Honours Class I 1974

Current Memberships - Professional Societies

• Royal Australasian College of Physicians
• Royal College of Pathologists of Australasia
• Australasian Society for Infectious Diseases
• Australasian Society for HIV Medicine
• American Society for Microbiology
• Australasian Society for Antimicrobials
• Infectious Diseases Society of America
• International Society for Heart and Lung transplantation
• International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• Transplant Infectious Diseases
• European Society for Clinical Microbiology and Infectious Diseases
• The Transplant Society
• Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

• 1986- Member, Drug and Therapeutics Committee, St. Vincent's Hospital
• 1988 - Accreditor, National Association of Testing Authorities
• 1989-97 Member, N.S.W. State Committee, Royal Australasian College of Physicians
• 1990- Examiner, Royal Australasian College of Pathologists
• 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
• 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
• 1997-99 President, Australasian Society for HIV Medicine
• 2000-10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
• 2009-13 Co-chair, Australian and New Zealand Mycoses Interest Group
• 2010 - Examiner, Royal Australasian College of Physicians
• 2012- Scientific Committee member (HIV and Infectious Diseases), International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• 2012- Scientific Committee member, International Society for Heart and Lung Transplantation • 2012- Scientific Committee member, Transplant Infectious Diseases
• 2013- President, Transplant Infectious Diseases
• 2013- Board Member, Medical Advances without Animals
• 2014 - Visiting Lecturer, The Academy of Medicine, Singapore
• 2014- Visiting International Professor, Royal College of Pathologists of Australasia

• Approximately 160 publications in refereed journals
• Joint lead, IATDMCT Guidelines on TDM of Echinocandins
• Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device. The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients. (In press).
• Proposer and Co-Convener – joint IATDMCT/TID/The Transplant Society (TTS) Conference, Hong Kong, 2016 in conjunction with TTS Conference
• Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014), ISHAM (Melbourne 2015)
• Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013) and Penang (2014).
• Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
• Coordinator of the Clinical Stream at the forth-coming ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
• Reviewer of approximately 15 manuscripts per year for the past 5 years in local and international journals

Employment

• Division of Clinical Pharmacology
  Karolinska Institutet
  Stockholm, Sweden
• Institute of Experimental and Clinical Pharmacology and Toxicology
  Saarland University, Homburg (Germany)

Education & Certification

• Habilitation with Venia Legendi for Pharmacology & Toxicology 
• PhD
• M.Sc., Pharmacist
• Clinical toxicologist certified by GTFCh

Professional Activities

• Memberships in IADTMCT, TIAFT, GTFCh (German speaking society of forensic chemistry), DPhG (German society of pharmaceutical sciences)
• Activities in IATDMCT: Vice chair young scientist committee, Member of communication commitee
• Executive and committee positions held: TIAFT (Young scientist committee member), GTFCh (Chair of the continuous education program)
• Number of publications: over 80 PubMed-listed and peer-reviewed articles, numerous book chapters
• Speaking engagements: Several invited talks at international conferences (USA, Europe, Asia)
• Professional appointments: Clinical toxicologist GTFCh

Dr Franck Saint-Marcoux is President of the TDM group of the French Society of Pharmacology and Therapeutics (SFPT) and Chair of the IATDMCT Pharmacometrics Committee. He is currently responsible for the Pharmacology and Pharmacokinetic Unit of the Pharmacology and Toxicology department of the Limoges University Hospital (France), and is a member of the INSERM research unit "Pharmacology of the immunosuppressive drugs in transplantation" directed by Prof. Pierre Marquet.

Dr Franck Saint-Marcoux obtained a Master of Advanced Studies in Pharmacy and a PhD in Pharmacokinetic Modelling in 2004. His research activity is focused on the development of PK tools useful for routine activity of TDM, mainly immunosuppressants, but also antibiotics or anticancer drugs. He is author or co-author of over 40 papers in peer-reviewed international journals.

Employment

Franck Saint-Marcoux is currently:

• Full Professor of Toxicology; Head of the Toxicology Department of the Faculty of Pharmacy, Limoges, France
• Hospital Practitioner; Head of the Clinical and Forensic Toxicology Unit of the Pharmacology and Toxicology Department, Limoges University Hospital, France
• Member of the INSERM research unit “Pharmacology of the immunosuppressive drugs in transplantation”, Limoges University, France
  (INSERM is the French Institute of Medical and Health Research)

Education & Certification

Franck Saint-Marcoux is PharmD, PhD

• Master of Advanced Studies in Clinical Pharmacy
• PhD in Pharmacokinetic Modelling

Professional Activities

• Member of the IATDMCT since 2003
• Councillor of the IATDMCT
• Chair of the IATDMCT Pharmacometrics Committee
• Past President of the TDM group of the French Society of Pharmacology and Therapeutics
• Author or co-author of over 50 papers in peer-reviewed international journals

Christoph Seger studied Chemistry and Biochemistry at the University of Vienna, Austria (PhD 2001, University of Vienna). After focusing on NMR based structure elucidation of Natural Products and peptides (Max Planck Institute for Biochemistry, Martinsried, Germany) for several years he took up a lecturer position at the Institute of Pharmacy at the University of Graz, Austria, followed by Post-Doc appointment at the Institute of Pharmacy at the University of Innsbruck, Austria. He obtained his venia legendi (Habilitation) at the University of Innsbruck in 2008 for his research focus on Pharmaceutical Analysis.

Since 2005 he is technical head of the ISO 15189 accredited Mass Spectrometry and Chromatography laboratory at the Central Institute of Medicinal and Chemical Laboratory Diagnostics (ZIMCL) / University Hospital Innsbruck, Austria which focuses on TDM and endocrinology testing. 
Besides serving as council member for the IATDMCT, where he is also ISD scientific committee member, he is a board member of the Austrian Society for Analytical Chemistry (ASAC) and the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC). He serves as review team I / II member for the Joint Committee for Traceability in Laboratory Medicine (JCTLM) Working Group and has been appointed as PT scheme leader for drugs of the Austrian Society for Quality Assurance and Standardization of Medical-Diagnostics (ÖQUASTA). 

He is involved in academic teaching at the University of Innsbruck, the Medical University Innsbruck and the UMIT. In addition he has supervised more than a dozen BA, MS, and PhD theses projects. His publication record currently holds 60+ peer reviewed papers and reviews, about 50 conference abstracts in peer reviewed journals, 40 invited lectures and more than 130 other conference contributions (lectures, poster presentations).